Recombinant Proteins iso9001 ISO13485
搜索
 > 【IL-6 R alpha】重组蛋白信息

IL-6 R alpha信息

英文名称:Interleukin-6 receptor alpha subunit
中文名称:白细胞介素-6受体α亚基
靶点别称:IL6RA,IL6RQ,IL6Q,Interleukin-6 Receptor alpha Subunit,sIL6R,gp80,IL-6R subunit alpha,Membrane glycoprotein 80,IL6R,Interleukin 6 Receptor,IL-6 Receptor Subunit Alpha,CD126 Antigen,IL-6R 1,IL-6RA,Interleukin-6 Receptor Subunit Alpha,IL-6R-Alpha,IL-6R-1,CD1
上市药物数量:3
临床药物数量:12
最高研发阶段:批准上市

IL-6 R alpha Molecule Synonym Name

IL6R,CD126,IL-6R-1,IL-6RA,IL6RA,IL-6R-alpha,IL6RQ,gp80

IL-6 R alpha 分子背景

Interleukin 6 receptor (IL6R) is also known as CD126 (Cluster of Differentiation 126) , is a potent pleiotropic cytokine that regulates cell growth and differentiation of various tissues, and is known particularly for its role in the immune response and acute phase reactions. IL6R is a protein complex consisting of a IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. IL6R also denotes the human gene encoding this subunit. Alternatively spliced transcript variants encoding distinct isoforms have been reported. IL6R subunit also shared by many other cytokines. The soluble form of IL6R arises from proteolytic cleavage of membrane-bound IL6Rα, and acts agonistically by making the IL6 ligand accessible to the signal transducer gp130. Dysregulated production of IL6 and IL6R are implicated in the pathogenesis of several inflammatory diseases and malignancies such as multiple myeloma, rheumatoid arthritis, or osteoporosis, and it has been reported that a humanized anti-IL6R monoclonal antibody is a promising agent applicable to the therapeutic approach for IL6 driven diseases. Interleukin-6 receptor has been shown to interact with Interleukin 6 and Ciliary neurotrophic factor.

IL-6 R alpha 参考文献

IL-6 R alpha上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Sarilumab REGN-88; SAR-153191 批准上市 赛诺菲, Regeneron Pharmaceuticals Inc Kevzara Japan 类风湿关节炎 Sanofi 2017-05-22 巨细胞性动脉炎, 类风湿关节炎, 强直性脊柱炎, 新型冠状病毒肺炎, 风湿性多肌痛, 幼年型类风湿性关节炎, 冠状病毒感染, 葡萄膜炎 详情
Satralizumab RG-6168; SA-237 批准上市 中外制药株式会社 エンスプリング, Enspryng United States 视神经脊髓炎 Genentech Inc 2020-06-29 视神经脊髓炎 详情
Tocilizumab 托珠单抗 MRA; rhPM-1; RG-1569; HPM-1; MRA-SC; R-1569; RO-48775533 批准上市 中外制药株式会社 Actemra/RoActemra, Actemra, RoActemra, 雅美罗 United States 系统性硬化相关肺间质疾病 Genentech Inc 2005-04-11 新型冠状病毒肺炎, 肝细胞癌, 非霍奇金淋巴瘤, 淋巴瘤, 急性髓细胞样白血病, 结直肠癌, 滤泡中心淋巴瘤, 多中心卡斯特莱曼病, 大动脉炎, 系统性硬化相关肺间质疾病, 膀胱癌, 幼年型类风湿性关节炎, 肝癌, 移行细胞癌, 弥漫性大B-细胞淋巴瘤, 强直性脊柱炎, 系统性硬皮病, 类风湿关节炎, 系统性少年特发性关节炎, 巨细胞性动脉炎, 胆管癌, 细胞因子释放综合征, B-细胞淋巴瘤 详情

IL-6 R alpha临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Atexakin alfa r-IL-6; SON-080 临床二期 默克雪兰诺, Weizmann Institute Of Science 周围神经系统疾病, 糖尿病神经病变 详情
Olamkicept FE-301; TJ-301; CR-5/18; FE-999301 临床二期 Conaris Research Institute 炎症性肠疾病, 溃疡性结肠炎, 克罗恩病 详情
Tocilizumab biosimilar (AryoGen Pharmed) 临床三期 Aryogen Biopharma 类风湿关节炎 详情
Levilimab BCD-089 临床三期 Biocad 类风湿关节炎, 新型冠状病毒肺炎 详情
Vobarilizumab ALX-0061; ANTI-IL-6R; 20A11-9mer-ALB11; Anti-IL-6R Nanobody 临床二期 Ablynx 类风湿关节炎, 系统性红斑狼疮 详情
Tocilizumab biosimilar (Fresenius kabi) MSB-11456 临床三期 默克雪兰诺 类风湿关节炎, 自身免疫疾病 详情
CMAB806 CMAB-806 临床三期 泰州迈博太科生物技术有限公司 类风湿关节炎, 关节炎 详情
Recombinant humanized anti-IL-6R antibody (Livzon Group) 临床三期 丽珠医药集团股份有限公司 类风湿关节炎 详情
Recombinant humanized anti-IL-6R monoclonal antibody (Beijing VDJBio) 临床一期 北京伟德杰生物科技有限公司 类风湿关节炎 详情
Recombinant humanized anti-IL-6R antibody (Hisun Pharma) 临床三期 浙江海正药业股份有限公司 类风湿关节炎, 关节炎 详情
Tocilizumab biosimilar (Bio-Thera Solutions) BAT-1806 临床三期 百奥泰生物制药股份有限公司 类风湿关节炎 详情

消息提示

请输入您的联系方式,再点击提交!

确定